CA Patent

CA2776296A1 — Therapeutic uses of pharmaceutical compositions

Assigned to Boehringer Ingelheim International GmbH · Expires 2011-04-07 · 15y expired

What this patent protects

The present invention relates to therapeutic uses of pharmaceutical compositions or combinations of a DPP-4 inhibitor with metformin.

USPTO Abstract

The present invention relates to therapeutic uses of pharmaceutical compositions or combinations of a DPP-4 inhibitor with metformin.

Drugs covered by this patent

Jardiance (empagliflozin) · Boehringer Ingelheim

Patent Metadata

Patent number: CA2776296A1
Jurisdiction: CA
Classification: —
Expires: 2011-04-07
Drug substance claim: No
Drug product claim: No
Assignee: Boehringer Ingelheim International GmbH
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.